Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Ipilimumab treatment decreases monocytic MDSCs and increases CD8 effector memory T cells in long-term survivors with advanced melanoma.

de Coaña YP, Wolodarski M, Poschke I, Yoshimoto Y, Yang Y, Nyström M, Edbäck U, Brage SE, Lundqvist A, Masucci GV, Hansson J, Kiessling R.

Oncotarget. 2017 Mar 28;8(13):21539-21553. doi: 10.18632/oncotarget.15368.

2.

IL-15, TIM-3 and NK cells subsets predict responsiveness to anti-CTLA-4 treatment in melanoma patients.

Tallerico R, Cristiani CM, Staaf E, Garofalo C, Sottile R, Capone M, Pico de Coaña Y, Madonna G, Palella E, Wolodarski M, Carannante V, Mallardo D, Simeone E, Grimaldi AM, Johansson S, Frumento P, Gulletta E, Anichini A, Colucci F, Ciliberto G, Kiessling R, Kärre K, Ascierto PA, Carbone E.

Oncoimmunology. 2016 Dec 7;6(2):e1261242. doi: 10.1080/2162402X.2016.1261242. eCollection 2017.

3.

[Hedgehog inhibitors. New promising treatment of advanced basal cell carcinoma].

Wolodarski M, Lapins J, Hansson J.

Lakartidningen. 2013 Apr 24-May 6;110(17-18):886-8. Review. Swedish. No abstract available.

PMID:
23717940
4.

[Paradigmatic shift in oncology: individualized melanoma treatment].

Hansson J, Djureen-Mårtenson E, Edvinsson F, Falkenius J, Friesland S, Masucci G, Månsson-Brahme E, Ragnarsson-Olding B, Sjödin H, Wolodarski M, Frohm-Nilsson M, Lapins J.

Lakartidningen. 2011 May 18-24;108(20):1092-3. Swedish. No abstract available.

PMID:
21815339

Supplemental Content

Loading ...
Support Center